|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study investigated whether multidisciplinary disease management programs (MDPs) exert the same effects in heart failure (HF) patients across risk levels stratified by galectin-3 (Gal-3) level and what factors are associated with inadequate effectiveness of MDP.
|
27443525 |
2017 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 overexpression and secretion is associated with several diseases and is extensively studied in the context of fibrosis, heart failure, atherosclerosis and diabetes mellitus.
|
29344292 |
2018 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To assess the expression of circulating miRNAs (miR-1, miR-21 and miR-208a) in patients with symptomatic heart failure (HF), and to investigate the relationship between expression of these miRNAs and secretion of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and galectin-3.
|
26498537 |
2015 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We hypothesize that plasma levels of Gal-3 and fibulin-1 are elevated in HF patients with DM and are associated with reduced LV contractile reserve in these patients.
|
28068900 |
2017 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We examined the association of arterial stiffness with galectin-3 levels in patients with HF of ischemic etiology.
|
29968538 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The goal of this study is to determine the cardiac localization and the time-course of galectin-3 expression in heart failure after viral inoculation with EMCV.
|
30673749 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate the relationship between the presence of fragmented QRS (fQRS) on electrocardiogram (ECG) and plasma galectin-3 levels in patients with heart failure (HF) and severely decreased left ventricular ejection fraction (LVEF ≤ 35%).
|
31155816 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To determine this, we prospectively analyzed data from 9,148 Atherosclerosis Risk in Communities (ARIC) Study participants with measured plasma galectin-3 levels (baseline, visit 4, 1996-98) and without prevalent chronic kidney disease (CKD) or heart failure.
|
28865675 |
2018 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the circulating decreased miR-1 and increased miR-21 expression are associated with NT-proBNP and galectin-3 levels in acute HF + DM.
|
31109008 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.
|
29844319 |
2018 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Myocardial biopsies obtained at an early stage of hypertrophy before apparent HF showed that expression of galectin-3 was increased specifically in the rats that later rapidly developed HF.
|
15520318 |
2004 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study evaluates the prognostic value of repeated time-dependent galectin-3 measurements in acute HF patients.
|
29187387 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) and soluble suppression of tumorigenicity 2 (ST2) are very interesting biomarkers for heart failure and myocardial fibrosis.
|
31622239 |
2020 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
These findings show that although an excess of cardiac and systemic Gal-3 is present in patients with HF of hypertensive origin, this molecule is not associated with histological, molecular and biochemical parameters related to myocardial fibrosis in these patients.
|
25684565 |
2015 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We undertook metabolomic and lipidomic phenotyping of a cohort of heart failure (HF) patients and utilized Multiple Regression Analysis (MRA) to identify associations to CPET and HFBio test performance (peak oxygen consumption (Peak VO2), oxygen uptake efficiency slope (OUES), exercise duration, and minute ventilation-carbon dioxide production slope (VE/VCO2 slope), as well as the established HF biomarkers of inflammation C-reactive protein (CRP), beta-galactoside-binding protein (galectin-3), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP)).
|
31220103 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3) is involved in fibrosis and heart failure.
|
31772609 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, inhibition of galectin‑3 by intravenous tail vein injection of a galectin‑3‑targeting short hairpin RNA‑expressing vector during hypertension‑induced heart failure in Dahl hypertensive rats increased rat survival and body weight.
|
29286090 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We are presenting an electrochemical immunosensor for the determination of Galectin-3 (Gal-3), a biomarker of heart failure.
|
29096363 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Circulating galectin-3 (Gal-3) is elevated and significantly correlates with all-cause and cardiovascular mortality in patients with heart failure.
|
30477951 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have additional benefit in assessment of cardiac remodeling or differentiation of HF subtypes.
|
29682806 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
CT-1 (cardiotrophin-1) and Gal-3 (galectin-3) are increased in HF and associated with myocardial fibrosis.
|
30612490 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
We sought to find whether galectin-3 has a prognostic value in patients with heart failure and a reduced left ventricular ejection fraction undergoing ablation of persistent atrial fibrillation.
|
30067817 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 (Gal-3), indicating cardiac fibrosis, is a documented biomarker of prognosis in HF.
|
28318874 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Galectin-3 was not associated with either HF with reduced EF or HF with preserved EF.
|
31645163 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Using a random-effects meta-analysis, we found an HR of 1.10 (95% CI 1.05 to 1.14) for all-cause mortality, 1.22 (95% CI 1.05 to 1.39) for CVD mortality, and 1.12 (95% CI 1.04 to 1.21) for HF risk for each 1 SD increase in galectin-3 level.
|
28247849 |
2017 |